---
import PageHero from "../../components/PageHero.astro";
import Layout from "../../layouts/Layout.astro";
import CTA from "../../components/CTA.astro";
import InternalNavigation from "../../components/InternalNavigation.astro";
const internalNavLinks = [
  { href: "study-design", label: "Study design", active: true },
  { href: "safety", label: "Safety" },
];
import Table from "../../components/Table/Table.astro";
import TableHeader from "../../components/Table/TableHeader.astro";
import TableData from "../../components/Table/TableData.astro";

//Table headers - Study design
const mainHeaders = [
  { label: "" },
  {
    label: "<span>Study 1<sup>1,2,8</sup></span>",
    subLabel: "ENB-002-08/ENB-003-08",
  },
  { label: "<span>Study 2<sup>1,6</sup></span>", subLabel: "ENB-010-10" },
  {
    label: "<span>Study 3<sup>1,3,10</sup></span>",
    subLabel: "ENB-006-09/ENB-008-10",
  },
  {
    label: "<span>Study 4<sup>7</sup></span>",
    subLabel: "ENB-009-10<br>Not included in the current STRENSIQ label",
    classModifier: "study-4",
  },
];
import studyData from "./data/study";

//Table headers - Adverse reactions
const subHeaders = [
  { label: "" },
  { label: "Perinatal/Infantile-onset HPP", colspan: 3 },
  { label: "Juvenile-onset HPP" },
];
const subSubHeaders = [
  {
    label: "Adverse Reaction<br> Category or Term",
    classModifier: "cg",
  },
  {
    label: "STRENSIQ<br> ≤6 mg/kg per<br> week (N=66) n (%)",
    classModifier: "nb",
  },
  {
    label: "STRENSIQ<br> >6 mg/kg per<br> week<sup>b</sup> (N=13) n<sup>a</sup> (%)",
    classModifier: "nb",
  },
  { label: "TOTAL<br> (N=79) n (%)", classModifier: "nb" },
  { label: "STRENSIQ<br> (N=20) n (%)" },
];
import data from "./data/safety";
import References from "../../components/References.astro";
---

<Layout title="Overview">
  <PageHero
    pageId="clinical-data"
    classNames="clinical-data-overview__page-hero"
    shapeSecondary={false}
  >
    <h2 class="page-hero__subtitle">To treat hypophosphatasia</h2>
    <h1 class="page-hero__title">
      Get straight to<br /> the source with STRENSIQ<sup>1</sup>
    </h1>
    <picture class="page-hero__image-container" slot="hero-image">
      <source
        media="(min-width: 1024px)"
        srcset="/assets/images/clinical-data/overview/safety-helmet-desktop.png"
      />
      <source
        media="(min-width: 425px)"
        srcset="/assets/images/clinical-data/overview/safety-helmet-tablet.png"
      />
      <img
        src="/assets/images/clinical-data/overview/safety-helmet-mobile.png"
        alt=""
      />
    </picture>
  </PageHero>
  {
    internalNavLinks && (
      <InternalNavigation
        items={internalNavLinks}
        heading="Overview"
        icon={false}
      />
    )
  }

  <div class="clinical-data-overview__study-design__head">
    <div class="wrapper">
      <h2 class="clinical-data-overview__study-design--title">
        STRENSIQ is the only treatment for adults and children with
        perinatal/infantile- and juvenile-onset hypophosphatasia<sup>1</sup>
      </h2>
    </div>

    <div class="clinical-data-overview__study-design--square">
      <div class="wrapper">
        <p class="clinical-data-overview__paragraph">
          7 years of demonstrated long-term safety and efficacy data<sup
            >1-8</sup
          >
          <!-- <span class="clinical-data-overview__white-line"></span> -->
        </p>
      </div>
    </div>
  </div>

  <section
    id="study-design"
    class="wrapper wrapper--only-left wrapper--only-left--mobile-only section clinical-data-overview__study-design"
  >
    <div class="clinical-data-overview__study-design__table">
      <Table>
        <!--Table headers -->
        <TableHeader slot="header" mainHeaders={mainHeaders}>
          <tr slot="aditional-header" class="buttons-table-header">
            <th></th>
            <th colspan="2">
              <a href="/clinical-data/infants-young-children" class="button">
                Infants / young children</a
              >
            </th>
            <th class="buttons-container">
              <div class="buttons-container">
                <a href="/clinical-data/children" class="button">Children</a>
                <a href="/clinical-data/adolescents" class="button"
                  >Adolescents</a
                >
              </div>
            </th>
            <th>
              <a href="/clinical-data/adults" class="button button--adults"
                >Adults/adolescents</a
              >
            </th>
          </tr>
        </TableHeader>
        <!--Table data -->
        <TableData slot="body" data={studyData} />

        <div slot="footer" class="table__footer">
          <span
            ><sup class="positioned">a</sup>Adolescents in the study were aged
            13 to 17 years.<sup>9</sup></span
          >
          <span
            ><sup class="positioned">b</sup>Adults in the study were aged ≥18
            years and 12 of 13 had pediatric-onset HPP.<sup>7</sup></span
          >
        </div>
      </Table>
    </div>
  </section>

  <section id="safety" class="section clinical-data-overview__safety">
    <div class="clinical-data-overview__safety__description">
      <div class="wrapper">
        <div>
          <h2 class="clinical-data-overview__safety__description--title">
            STRENSIQ has a well-established safety profile, evidenced by 7 years
            of data<sup>11</sup>
          </h2>
          <p class="clinical-data-overview__safety__description--paragraph1">
            STRENSIQ has been rigorously studied across 8 clinical trials, with
            over 1,500 patient-years of registry data, and more than 7 years of
            postmarket experience.<sup>12-14</sup>
          </p>
          <p
            class="clinical-data-overview__safety__description--paragraph2 desktop--only"
          >
            Clinical practice guidelines for hypophosphatasia are not currently
            available in the United States. When considering treatment,
            healthcare providers should use their clinical judgment based on
            individual patient needs.<sup>15,16</sup>
          </p>
        </div>

        <div
          class="clinical-data-overview__safety__anotations clinical-data-overview__safety__anotations--desktop desktop--only"
        >
          <p>
            <sup>a</sup>These data reflect exposure to STRENSIQ in 99 patients
            with perinatal/infantile- or juvenile-onset HPP (age 1 day to 58
            years) treated with STRENSIQ, most for more than 2 years (range 1
            day to 312 weeks [78 months]): 51 patients received at least 96
            weeks (24 months) of treatment and 39 patients received 168 weeks
            (42 months) or more of treatment.
          </p>
          <p>
            <sup>b</sup>Adverse reactions are from the combined period of 6
            mg/kg and above (ie, total drug exposure regardless of starting dose
            and intermediary doses as long as the patient reached doses &#62;6
            mg/kg).
          </p>
          <p>
            <sup>c</sup>Other injection site reactions include injection site
            rash, inflammation, papule, hemorrhage, hematoma, urticaria, warmth,
            calcification, mass, scar, and cellulitis.
          </p>
          <p>
            <sup>d</sup>Other lipodystrophy includes lipohypertrophy.
          </p>
          <p>
            <sup>e</sup>Other hypersensitivity reactions include
            erythema/redness, pyrexia/fever, irritability, nausea, pain,
            rigor/chills, oral hypoesthesia, headache, flushing, and
            anaphylaxis.
          </p>
        </div>
      </div>
    </div>

    <h4 class="clinical-data-overview-container__panel-title mobile--only">
      Most frequently reported adverse reactions (≥10% of patients) from
      STRENSIQ Prescribing Information<sup>1,a</sup>
    </h4>

    <div
      class="wrapper wrapper--only-left wrapper--only-left--only-mobile clinical-data-overview__safety__table"
    >
      <h4 class="clinical-data-overview-container__panel-title desktop--only">
        Most frequently reported adverse reactions (≥10% of patients) from
        STRENSIQ Prescribing Information<sup>1,a</sup>
      </h4>
      <!-- TODO: Is necesary to refactor title prop in Table component to be able to send html -->
      <div class="mtable wrapper--only-right">
        <Table className="safety-table">
          <TableHeader
            slot="header"
            subHeaders={subHeaders}
            subSubHeaders={subSubHeaders}
          />
          <TableData slot="body" data={data} className="no-padding" />
        </Table>
      </div>
    </div>

    <div
      class="wrapper clinical-data-overview__safety__anotations mobile--only"
    >
      <p>
        <sup>a</sup>These data reflect exposure to STRENSIQ in 99 patients with
        perinatal/infantile- or juvenile-onset HPP (age 1 day to 58 years)
        treated with STRENSIQ, most for more than 2 years (range 1 day to 312
        weeks [78 months]): 51 patients received at least 96 weeks (24 months)
        of treatment and 39 patients received 168 weeks (42 months) or more of
        treatment.
      </p>
      <p>
        <sup>b</sup>Adverse reactions are from the combined period of 6 mg/kg
        and above (ie, total drug exposure regardless of starting dose and
        intermediary doses as long as the patient reached doses &#62;6 mg/kg).
      </p>
      <p>
        <sup>c</sup>Other injection site reactions include injection site rash,
        inflammation, papule, hemorrhage, hematoma, urticaria, warmth,
        calcification, mass, scar, and cellulitis.
      </p>
      <p>
        <sup>d</sup>Other lipodystrophy includes lipohypertrophy.
      </p>
      <p>
        <sup>e</sup>Other hypersensitivity reactions include erythema/redness,
        pyrexia/fever, irritability, nausea, pain, rigor/chills, oral
        hypoesthesia, headache, flushing, and anaphylaxis.
      </p>
      <p class="clinical-data-overview__safety__anotations--disclaimer">
        Clinical practice guidelines for hypophosphatasia are not currently
        available in the United States. When considering treatment, healthcare
        providers should use their clinical judgment based on individual patient
        needs.<sup>15,16</sup>
      </p>
    </div>
  </section>

  <CTA
    heading="Lay the groundwork for their future with HPP"
    linkText="Infants/young children"
    linkUrl="/clinical-data/infants-young-children"
    classNames="clinical-data-overview__cta"
  />
  <References slot="references">
    <p>
      <strong>References: 1.</strong> STRENSIQ. Package insert. Alexion Pharmaceuticals,
      Inc. <strong>2.</strong> Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement
      therapy in life-threatening hypophosphatasia. <i>N Engl J Med.</i> 2012;366(10):904-913.
      <strong>3.</strong> Whyte MP, Madson KL, Phillips D, et al. Asfotase alfa therapy
      for children with hypophosphatasia. <i>JCI Insight.</i>
      2016;1(9):e85971. <strong>4.</strong> Whyte MP, Rockman-Greenberg C, Moseley
      S, Denker AE, McAlister W. Sustained radiographic and functional improvements
      with asfotase alfa treatment from up to 7 years in children with hypophosphatasia.
      Presented at: 8th Biennial International Conference on Children's Bone Health
      (ICCBH); June 10-13, 2017; Wurzburg, Germany.
      <strong>5.</strong> Whyte M, Bishop N, Hasan J, et al. Safety profile of asfotase
      alfa treatment of patients with hypophosphatasia: a pooled analysis. <i
        >J Endocr Soc.</i
      > 2019;3(suppl 1):OR13-4. <strong>6.</strong> Hofmann CE, Harmatz P, Vockley
      J, et al. Efficacy and safety of asfotase alfa in infants and young children
      with hypophosphatasia: a phase 2 open-label study. <i
        >J Clin Endocrinol Metab.</i
      > 2019;104(7):2735-2747. <strong>7.</strong> Kishnani PS, Rockman-Greenberg
      C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for
      adults and adolescents with hypophosphatasia.
      <span style="font-style: italic;">Bone</span>. 2019;121:149-162. <strong
        >8.</strong
      > Whyte MP, Simmons JH, Moseley S, et al. Asfotase alfa for infants and young
      children with hypophosphatasia: 7 year outcomes of a single-arm, open-label,
      phase 2 extension trial. <span style="font-style: italic;"
        >Lancet Diabetes Endocrinol</span
      >. 2019;7(2):93-105. <strong>9.</strong> Data on file. Alexion Pharmaceuticals,
      Inc. <strong>10.</strong> Whyte MP, Rockman-Greenberg C, Moseley S, Denker
      AE, Watsky E, McAlister WH. Sustained radiographic and functional improvements
      with asfotase alfa treatment for up to 7 years in children with hypophosphatasia.
      Poster presented at: International Congress of Inborn Errors of Metabolism
      (ICIEM); Sept 5–8, 2017; Rio de Janeiro, Brazil. <strong>11.</strong> Whyte
      MP, Bishop N, Hasan J, et al. Safety profile of asfotase alfa treatment of
      patients with hypophosphatasia: a pooled analysis. Poster presented at: 9th
      Biennial International Conference on Children’s Bone Health (ICCBH); June 22-25,
      2019; Salzburg, Austria. <strong>12.</strong> NIH US National Library of Medicine.
      ClinicalTrials.gov. Accessed April 20, 2023. <a
        href="https://clinicaltrials.gov/ct2/results?cond=hypophosphatasia&term=asfotase+alfa&cntry=&state=&city=&dist="
        target="_blank"
        >https://clinicaltrials.gov/ct2/results?cond=hypophosphatasia&term=asfotase+alfa&cntry=&state=&city=&dist=</a
      >
      <strong>13.</strong> FDA approves Strensiq™ (asfotase alfa) for treatment of
      patients with perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP).
      News release. Alexion Pharmaceuticals, Inc. October 23, 2015. Accessed April
      3, 2023. <a
        href="https://media.alexion.com/news-releases/news-release-details/fda-approves-strensiqtm-asfotase-alfa-treatment-patients"
        target="_blank"
        >https://media.alexion.com/news-releases/news-release-details/fda-approves-strensiqtm-asfotase-alfa-treatment-patients</a
      >
      <strong>14.</strong> Data on file. Alexion Pharmaceuticals, Inc. <strong
        >15.</strong
      > Rockman-Greenberg C, Josse R, Francis M, Mhanni A. Impact of discontinuing
      5 years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia:
      A case series. <i>Bone Rep.</i> 2022;17:101617. <strong>16.</strong> Bianchi
      ML, Bishop NJ, Guañabens N, et al; Rare Bone Disease Action Group of the European
      Calcified Tissue Society. Hypophosphatasia in adolescents and adults: overview
      of diagnosis and treatment. <i>Osteoporos Int.</i> 2020;31(8):1445–1460.
    </p>
  </References>
</Layout>
